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Abstract
Purpose Faecal incontinence is a physically, psychologically
and socially disabling condition. NICE guidance (2007) rec-
ommends surgical intervention, including sacral nerve stimu-
lation (SNS), after failed conservative therapies. The
FENIX™ magnetic sphincter augmentation (MSA) device is
a novel continence device consisting of a flexible band of
interlinked titanium beads with magnetic cores that is placed
around the anal canal to augment anal sphincter tone through
passive attraction of the beads. Preliminary studies suggest the
FENIX™MSA is safe, but efficacy data is limited. Rigorous
evaluation is required prior to widespread adoption.
Method and design The SaFaRI trial is a National Institute of
Health Research (NIHR) Health Technology Assessment
(HTA)-funded UK multi-site, parallel group, randomised con-
trolled, unblinded trial that will investigate the use of the
FENIX™MSA, as compared to SNS, for adult faecal incon-
tinence resistant to conservative management. Twenty sites
across the UK, experienced in the treatment of faecal inconti-
nence, will recruit 350 patients randomised equally to receive
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either SNS or FENIX™MSA. Participants will be followed-
up at 2 weeks post-surgery and at 6, 12 and 18months post-
randomisation. The primary endpoint is success, as defined by
device in use and ≥50 % improvement in the Cleveland Clinic
Incontinence Score (CCIS) at 18 months post-randomisation.
Secondary endpoints include complications, quality of life
and cost effectiveness.
Discussion SaFaRI will rigorously evaluate a new technology
for faecal incontinence, the FENIX™MSA, allowing its safe
and controlled introduction into current clinical practice.
These results will inform the future surgical management of
adult faecal incontinence.
Keywords Faecal incontinence . Sacral nerve stimulation .
FENIXTM . Randomised controlled trial . Surgery
Background
Faecal incontinence (FI) is a common and distressing condi-
tion with an estimated prevalence of 7.7 % (range 2.0–20.7%)
for the adult population [1]. It is more common in females and
with advancing age and is the second most common cause of
admission to a nursing home. It impacts on social, physical
and mental well-being and is a substantial burden on National
Health Service (NHS) resources [2].
Treatment strategies for adult FI are summarised in the
National Institute for Health and Care Excellence (NICE)
2007 guidance, which supports the use of sacral nerve stimu-
lation (SNS) for the treatment of adult FI refractory to conser-
vative measures [3]. SNS works by electrical stimulation of
the sacral (S2–S4) nerve roots, producing a combination of
anal sphincter augmentation and modulation of spinal/supra-
spinal pathways. It benefits from a two-stage procedure,
which enables the patient to assess acceptability and the clini-
cian to evaluate efficacy prior to permanent implantation. The
patient is asked to keep a bowel diary for the 2–3 weeks of
temporary stimulation, which allows the clinician to quantify
the degree of response. A positive response is defined as a
reduction in incontinence episodes or incontinence score of
≥50 % during the stimulation period [4].
SNS has been widely adopted and is currently considered
the standard of care for adults with moderate to severe faecal
incontinence. Although the short-term efficacy of SNS is
good, with 70–80 % of patients experiencing symptom im-
provement, some 25 % of patients suffer loss of efficacy with
time and a further 2–5% suffer irresolvable complications and
undergo explantation [5–7]. From a decision-to-treat perspec-
tive, the long-term efficacy is around 50 % [8]. SNS is also
very costly. The component costs alone (excluding other di-
rect and indirect medical costs) are £200 for the test stimula-
tion and £9393 for the permanent stimulator. A European trial
has calculated the 5-year cumulative costs for SNS at €22,150
per patient, which compared with €33,996 for a colostomy
and €3234 for conservative treatment [2]. Despite this, SNS
has been shown to be cost-effective. The incremental cost-
effectiveness ratio (ICER) for SNS is £25,070 per quality-
adjusted life year (QALY) gained, which is within the thresh-
old recommended by NICE as an effective use of NHS re-
sources [9].
Recently, a new device for adult FI has been introduced
into clinical practice—the FENIXTM Magnetic Sphincter
Augmentation Continence Restoration System (FENIXTM
MSA). It consists of a ring of 14 to 20 titanium beads with
magnetic cores that are linked together to form an annular
structure to be surgically placed around the anal sphincter
complex. To defecate, the patient strains in a normal way
and the force generated separates the beads to open the anal
canal. Continence is restored by means of passive attraction of
the beads. The FENIXTMMSA costs £4000. Data on efficacy
is limited to a few small single-centre studies [10, 11], a ret-
rospective case-matched comparison to the artificial bowel
sphincter where it compared favourably [12], and one small,
multicentre, feasibility study [13] that suggests a ≥50 % im-
provement in continence in 70 % of patients in the short term.
However, complications are reported in around 20 % of pa-
tients, leading to explantation in around 10 %.
In May 2012, the National Institute for Health Research Ho-
rizon Scanning Centre (NIHR HSC) reviewed the evidence on
FENIXTM MSA and concluded, “in order to determine its po-
tential place in the pathway of care for FI larger long term studies
of the safety, effectiveness and cost-effectiveness of FENIXTM
MSA in comparison to existing treatments are needed” [14].
In 2014, the NIHR HTA programme funded the SaFaRI
trial—sacral nerve stimulation versus the FENIX™ magnetic
sphincter augmentation for adult faecal incontinence: a
randomised investigation (Trial Registration: ISRCTN
16077538). The aim of the trial is to undertake a randomised
comparison of the FENIXTM MSA as compared to SNS in
terms of safety, efficacy, quality of life and cost-effectiveness.
This manuscript details the trial design. The results are expect-
ed to provide rigorous data on FENIXTM MSA, SNS and a
“no treatment” group that fail temporary SNS and are treated
by alternative means for the duration of trial recruitment. This
will allow healthcare providers to make informed decisions
about service provision and facilitate patient choice in the
treatment options for FI.
Methods
Overall trial aims
The SaFaRI trial will involve a thorough evaluation of the
FENIXTM MSA device, as compared to SNS, for the treat-
ment of adult FI. It will evaluate the short-term safety and
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efficacy of FENIXTM MSA and SNS in adult FI and assess
both devices in terms of impact on quality of life and cost-
effectiveness.
The primary outcome measure is success, as defined by
either FENIXTM MSA or SNS implant in use at 18 months
post-randomisation and with a ≥50 % improvement in Cleve-
land Clinic Incontinence Score (CCIS) [15]. Secondary out-
come measures will include the following: length of hospital
stay, complications, re-interventions, constipation scores,
quality of life and cost-effectiveness.
Trial sites and participating surgeons
The trial will recruit from at least 20 sites throughout the UK.
Participating sites must be an NHS hospital providing special-
ist treatment for adult FI with experience in the provision of
SNS and the facilities to perform endoscopic visualisation of
the colorectum, anorectal manometry and endoanal ultra-
sound. Participating surgeons should be members of The As-
sociation of Coloproctology of Great Britain and Ireland
(ACPGB&I) and must have experience of a minimum of ten
SNS implantations and a minimum of one observed
FENIXTM MSA procedure and two FENIXTM MSA proce-
dures under proctorship.
Trial population
FI is defined as the inability to control the passage of faeces
through the anus. For inclusion in the trial, conservative treat-
ments should have been tried and proven ineffective. Both the
technology under evaluation (FENIXTM MSA) and the com-
parator (SNS) will be evaluated on the same patient popula-
tion. Incontinence may be from any aetiology.
Eligible patients will be aged≥18 years, fit for and willing
to undergo either surgical intervention, and able to provide
written informed consent. They must have suffered from FI
for more than 6 months and experience ≥2 episodes of incon-
tinence per week. They should not have an anal sphincter
defect of ≥180° as documented on endoanal ultrasound scan.
Patients will be ineligible for the trial if they have had
previous surgical intervention (i.e. failed SNS treatment) for
FI, chronic gastrointestinal motility disorders causing diar-
rhoea, obstructive defaecation symptoms as determined by
an obstructed defecation score (OD score) >8, co-existent sys-
temic disease (e.g. scleroderma), active anorectal sepsis, a
colorectal cancer diagnosis within 2 years, external rectal pro-
lapse, immunocompromise or known requirement for future
magnetic resonance imaging (MRI).
Trial design
This is a UK multi-site, prospective, parallel group,
randomised controlled, unblinded trial to evaluate the safety
and efficacy of the FENIXTM MSA for moderate to severe
adult FI as compared to SNS. The Clinical Trials Research
Unit (CTRU) at the University of Leeds will co-ordinate the
trial. The follow-up period finishes 18 months after the last
participant is randomised. The University of Leeds is the trial
sponsor.
Participants will be randomised on a 1:1 basis to receive
either FENIXTM MSA or SNS. A computer-generated
minimisation programme that incorporates a random element
will be used to ensure treatment groups are well balanced for
prognostic factors: treating surgeon, gender, severity of incon-
tinence and degree of anal sphincter defect on endoanal ultra-
sound. (See Fig. 1: Trial schema).
Sample size
A total of 350 patients will be recruited with 175 being
randomised to each arm.
Recruitment
Patient recruitment will be over a 30-month period. Baseline
investigations will be as per institutional protocol, but must
include endoscopic visualisation of the colorectum (flexible
sigmoidoscopy as a minimum), anorectal manometry (puden-
dal nerve testing optional) and endoanal ultrasound. The du-
ration of the trial is expected to be 6 years including setup,
recruitment, follow-up and analysis.
Interventions
The control intervention of SNS implantation will be per-
formed in accordance with each site’s usual practice. SNS
implantation may be performed by either implantation of tem-
porary stimulating electrode followed by TINED lead, or
straight to TINED lead implant. A period of temporary stim-
ulation is used to assess participant response, which is record-
ed by means of a 2-week bowel diary. Response is assessed in
accordance with each site’s usual practice. The CCIS score
will be recorded for trial purposes regardless of how response
is assessed locally. If the response is positive (defined as a
≥50 % improvement in incontinence episodes or ≥50 % im-
provement in CCIS), the participant will proceed to a perma-
nent implant. If the response is negative, the temporary device
will be removed and the participant does not receive any fur-
ther trial intervention but will continue follow-up for the re-
quired 18-month follow-up period.
FENIXTMMSA implantationwill be standardised in accor-
dance with the manufacturer’s recommendations. Participants
will receive a single dose of broad-spectrum intravenous an-
tibiotics at induction of anaesthesia. Implantation of the device
will be under fluoroscopic guidance. Participants will be
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provided with laxatives/stool softeners and analgesics for a
period of 7–10 days post-operative.
Should a participant experience failure with either device,
which requires explantation, they will not be permitted to
undergo implantation of the alternative trial intervention dur-
ing the 18-month post-randomisation follow-up period. The
literature on SNS suggests that around 30 % of patients who
undergo a trial of temporary SNS will not have a positive
response and will not progress to a permanent implant. Within
the trial setting, they will be treated according to current prac-
tice, allowing the range of treatments to be captured.
Follow-up
The planned duration of the trial follow-up is until 18 months
after the last participant is randomised. Trial follow-up will
include participant review at 2 weeks post-operation and at
6, 12 and 18 months post-randomisation. Participants receiv-
ing SNS treatment will be seen at 2 weeks post-temporary
implant and if successful 2 weeks post-permanent implant.
Any further visits will be according to local clinical practice
and will be recorded on the follow-up case report forms
(CRFs).
Data collection and management
Participating sites will record participant data on trial-specific
paper CRFs. Clinical data will be collected at baseline, sur-
gery, 2 weeks post-operatively, and at 6, 12 and 18 months
post-randomisation. Participant-completed data will be col-
lected at baseline, 2 weeks post-operatively and at 6, 12 and
18 months post-randomisation. .
The CTRU (University of Leeds) will provide overall data
and trial management. Received trial data will be monitored
for quality and completeness. Missing and discrepant data will
be flagged and additional data validations raised as
appropriate.
An independent Data Monitoring and Ethics Committee
(DMEC) will review the safety and ethics of the trial.
Outcomes
The primary outcome measure is success, as defined by either
FENIXTM MSA or SNS implant in use at 18 months post-
randomisation and with a ≥50 % improvement in the CCIS
score. Secondary outcome measures will include the follow-
ing: length of hospital stay, complications, re-interventions,
constipation score, quality of life and cost-effectiveness.
Quality of life
Participants will complete a number of questionnaires de-
signed to capture FI symptoms (CCIS) [15], constipation
symptoms (OD score) [16], patient-reported quality of life
data (Faecal Incontinence Quality of Life Questionnaire
(FIQoL) [17], EQ-5D-5L® [18] and SF-12® [19]) and the costs
involved with each treatment, including costs allocated for
primary, community and social care services.
Participants will complete all questionnaires at baseline and
at 6, 12 and 18 months post-randomisation. In addition, par-
ticipants will complete the CCIS and the Health and Social
Care Resource use Questionnaire 2 weeks post-operatively
(only for temporary SNS, and FENIXTM MSA). For the per-
manent SNS, participants will complete the Health and Social
Care Resource use Questionnaire 2 weeks post-operatively.
Health economic assessment
An economic evaluation will be performed using the perspec-
tive of the NHS and social services to aid healthcare providers
to make informed decisions about value for money and the
future provision of the devices. The objective of the economic
evaluation is to identify the within-trial and long-term incre-
mental cost-effectiveness ratios for FENIXTM MSA versus
SNS for adult FI. The within-trial economic evaluation will
use QALYoutcomemeasures. Quality of life will bemeasured
using the EQ-5D-5L® [20, 21] at baseline and at 6, 12 and
18 months post-randomisation. This will limit the need to
interpolate quality of life between observation points and the
associated inaccuracy in the estimation of the Health-Related
Quality of Life (HRQoL) differences between groups [22].
However, whilst the EQ-5D-5L® is the NICE preferred mea-
sure of HRQoL, its sensitivity to detect changes in FI is un-
proven; we have therefore included the SF-12® as the source
of utility data and will undertake a secondary analysis using
the SF-12® to derive utility values [23] and present this along-
side the EQ-5D-5L® data [24].
NHS resource use associated with each device will be col-
lected either through the CRF (investigations, drugs and refer-
rals for other services), Hospital Episode Statistics (HES) data
(inpatient, outpatient and Accident and Emergency) or
through a participant questionnaire (contact with primary,
community and social care services). Unit costs for health
service resources will be obtained from national sources such
as the Personal Social Services Research Unit (PSSRU), the
British National Formulary (BNF) and NHS Reference cost
database. Where national unit costs are not available, the fi-
nance departments of NHS Trusts participating in the trial will
be asked to provide local cost data. The mean of these costs
will be used as the unit cost estimate in the analysis.
The non-parametric bootstrap method will be used to pro-
duce a within-trial probabilistic sensitivity analysis of the in-
cremental cost-effectiveness ratio. In addition to presenting
the expected incremental cost-effectiveness ratio, we will
present the scatterplot on the cost-effectiveness plane, the
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95 % cost effectiveness ellipse and the cost-effectiveness ac-
ceptability curve [25].
The exact structure and duration of the long-term cost-ef-
fectiveness model will be established in discussions with the
clinicians on the trial team and after analysis of the complica-
tion data observed in the trial. It is likely that the model will be
a Markov or semi-Markov state model. As far as possible, the
transition rates for the model will be estimated from the clin-
ical trial data. For model parameters for which data cannot be
collected within the trial, e.g. long-term outcomes, we will
follow the recommended best practice in identifying and syn-
thesising the best available evidence in the literature. The
long-term cost-effectiveness modelling will adopt the strate-
gies for addressing issues of perspective and discounting as
the within-trial analysis. We will, in addition, undertake an
expected value of information analysis.
Safety evaluation and reporting of adverse events
The term adverse events have been translated into complica-
tions for the purpose of safety reporting within the SaFaRI
trial. A complication is defined as an untoward medical event
in a participant, which has a causal relationship to the trial.
The trial includes the surgical intervention directly and any
trial-specific interventions. Information on all complications
will be collected whether volunteered by the participant, dis-
covered by investigator questioning or detected through phys-
ical examination or other investigation.
Statistical methods
Three hundred and fifty participants will be required to detect
at least a 20 % difference in the percentage of successes at
18 months post-randomisation (where success is defined as a
device in use and ≥50 % CCIS improvement from baseline)
between FENIXTM MSA and SNS at 5 % level of signifi-
cance, 90 % power, assuming approximately 40 % success
on the SNS arm and allowing for 20 % loss to follow-up.
Analyses will be performed on an intention-to-treat (ITT)
basis (primary analysis), where participants will be included
according to the surgical procedure they were randomised to,
and by actual treatment group, where participants will be in-
cluded according to the surgery actually received (SNS device
or FENIXTM MSA device implantation). All hypothesis tests
will be two-sided and use a 5 % significance level.
Analyses will exclude training cases, although data collect-
ed on training cases will be summarised. Analysis and
reporting will be in line with Consolidated Standards of
Reporting Trials (CONSORT) guidelines [26]. For the prima-
ry analysis, multi-level logistic regressionwill be used, includ-
ing adjustment for the factors included in the minimisation
algorithm.
Secondary endpoints including SF-12®, EQ-5D-5L®, CCIS
and OD-score recorded at baseline and at 6, 12 and 18 months
post-randomisation will be analysed using random effects
(multi-level) models to account for the hierarchical nature of
repeated measures data. The models will include adjustments
for minimisation factors, and a categorical covariate will be
used to assess the effect of length of time of device in use on
these endpoints.
Pattern-mixture multi-level models, which will treat all par-
ticipant data observed after the removal of their device
(explant) as missing data, but also account for the informative
nature of the missing data, will be fitted to the secondary
endpoints outlined above. Note that this is in contrast to the
random effects models outlined above, which incorporate data
from participants ‘post-explant’. Therefore, the results yielded
by the pattern-mixture multi-level models will act as sensitiv-
ity analyses, which can be used to explore the potential issue
of disparity in treatment of participants post-explant in each
treatment arm.
A subgroup analysis will be performed on participants in
the FENIXTM arm in order to explore which potential patients
could benefit most from FENIXTM. A multi-level logistic re-
gression model will be fitted using the primary endpoint, and
the effects of various patient-level covariates (e.g. age, gender,
baseline quality of life) on the odds of ‘success’ will be
assessed.
Data collected on the safety of FENIXTM MSA and SNS
will be analysed using multi-level logistic regression. No for-
mal interim analyses are planned; hence, no statistical testing
will take place until final analysis.
Trial organisation
The SaFaRI trial is funded by the NIHR HTA programme
(grant reference 12/35/07). The trial is sponsored by the Uni-
versity of Leeds. Trial supervision will be established accord-
ing to the principles of Good Clinical Practice (GCP) and in
line with the NHS Research Governance Framework (RGF).
This will include establishment of a core Project Team, Trial
Management Group (TMG), an independent Trial Steering
Committee (TSC) and DMEC.
Ethical considerations
The trial will be conducted in accordance with the principles
of GCP in clinical trials, the NHS RGF and through adherence
to CTRU SOPs. The trial will operate using the recommenda-
tions guiding physicians in biomedical research involving hu-
man subjects adopted by the 18th World Medical Assembly,
Helsinki, Finland, 1964, amended at the 64th World Medical
Association General Assembly, Fortaleza, Brazil, October
2013 [27]. Ethical approval will be sought through NRES.
The trial will be submitted to and approved by a REC and
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the appropriate site-specific assessor for each participating site
prior to any recruitment.
Discussion
New technologies have often been introduced into clinical
practice without rigorous evaluation of safety, efficacy and
cost-effectiveness. Objective assessment has been overlooked
due to the intrinsic appeal of new innovation, the need to be a
part of a ‘pioneering group’, or worse, due to the financial
incentives from industry. Once introduced, low-grade obser-
vational evidence is often used to keep practices going. As a
result, it has often been easier to ‘stop them starting’ than to
‘start them stopping’. Ideally, any new technology introduced
into clinical practice should be simultaneously evaluated, and
in most cases the best way of doing this is by randomised
comparison with an already established technique. The SaFa-
RI trial has been designed to comprehensively achieve a thor-
ough evaluation of the FENIXTM MSA device, as compared
to SNS, for the treatment of adult FI, so as to aid healthcare
providers to make informed decisions about value for money
and future provision of such technology.
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